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Background: The risk of life-threatening and invasive infections with encapsulated bacteria is increased in patients with
hyposplenia or asplenia. We report a case of recurrent invasive pneumococcal meningitis in a woman with previous
unknown hyposplenia. She was vaccinated after the first episode of meningitis and developed sufficient levels of
pneumococcal antibodies. The pneumococcal strains isolated were serotype 7 F and 17 F. To our knowledge, there has
been no previously reported case of recurrent invasive pneumococcal disease in a pneumococcal vaccinated adult with
hyposplenia and apparently sufficient antibody response.
Case presentation: We report the course of a 38-year-old Caucasian woman presenting with recurrent episodes
of invasive pneumococcal disease (IPD) and previously unknown hyposplenia. Hyposplenia was discovered during
the second episode of IPD and no underlying medical condition was found. Despite immunization against S. pneumoniae
and measurement of what was interpreted as protective levels of serotype-specific IgG antibodies after vaccination, the
patient suffered from a third episode of IPD.
Conclusions: Individuals with predisposing medical conditions or a history of severe infections with encapsulated
bacteria should be screened for spleen dysfunction. If splenic function is impaired, prevention against severe invasive
infection with encapsulated bacteria are a major priority.
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Streptococcus pneumoniae may cause severe invasive
pneumococcal disease (IPD) which includes pneumonia,
sepsis and meningitis [1]. The spleen plays important
roles in antigen processing. Initiation of an immuno-
logical response, production of specific antibodies and
splenic macrophages are important for removal of encap-
sulated bacteria and intra-erythrocytic parasites. Thus,
hyposplenic or asplenic patients are at increased risk for
fulminant and life-threatening infections with encapsu-
lated bacteria, most likely due to lack of splenic filtering
and decreased production of specific antibodies and me-
mory B lymphocytes [2,3]. Patients with hyposplenia or
asplenia have reduced levels of IgM memory B cells and
IgM anti-pneumococcal antibodies, causing reduced abil-
ity to produce protective antibodies against polysaccharide
antigens and hence possible vaccine failure [2,4,5]. The* Correspondence: cfischer@dadlnet.dk
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unless otherwise stated.risk of severe invasive infections with encapsulated
bacteria in splenectomised patients is more than 50-times
higher than in the general population, and 50-90% of the
cases are caused by S. pneumoniae, followed by H. influen-
zae and N. meningitidis [6].
Asplenia refers to the absence of the spleen, a rare con-
genital disorder and most often a result of surgery. Hypos-
plenia is regarded as an acquired disorder associated with
several medical diseases, and sometimes accompanied by a
reduction in spleen size. The most frequent hyposplenia-
associated disorders are severe liver disease, ulcerative col-
itis, celiac sprue, and lupus. Hemoglobinopathies, such as
sickle cell disease and the thalassemia’s, are also important
causes of functional hyposplenia [2]. Prevention of IPD in
patients with hyposplenia includes education, vaccination
and antibiotic prophylaxis [7]. However, IPD can occur even
in patients who have received pneumococcal immunization
and antibiotic prophylaxis.
To our knowledge, this is the first reported case of recur-
rent IPD in a pneumococcal vaccinated adult with hypos-
plenia and an estimated sufficient antibody response.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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from the Danish Data Protection Agency and the local
ethics committee and in accordance with the Declaration
of Helsinki.
Case presentation
First episode of IPD
A 38-year-old Caucasian woman was hospitalized in
2008 with IPD (serotype 7 F) causing meningitis, septic
shock and disseminated intravascular coagulation (DIC).
Sequelae included total hearing loss treated with bilat-
eral cochlear implants and amputation of the four lateral
toes of the left foot. Hereditary immunodeficiency was
suspected, as a one-year-old daughter was hospitalized
with pneumococcal meningitis (serotype 7 F) one month
earlier. Immunological investigation of the patient and her
daughter included assessment of complement activation,
fraction and concentrations of T, B and NK lymphocytes
and subpopulations, proliferative response of CD4 T-cells,
and Toll-like-receptor-stimulation. No signs of immuno-
deficiency were found. The only abnormal finding was a
low level of IgM-positive CD27 memory B cells in the
mother. The child was too young for assessment of mem-
ory B cells. No screening for impaired spleen function was
made at that time. The patient was immunized with a
23-valent pneumococcal polysaccharide vaccine (PPV23,
Pneumovax®, Sanofi Pasteur MSD) one month after ad-
mission, but measurement of the vaccination response
was not performed. Retrospective analysis of serum IgG-
antibody-levels against 14 representative serotypes was
performed on samples taken 5 days and 20 days after
debut (Table 1). A cut-off level of at least 0.35 μg/mL was
estimated as a protective level against IPD. Antibody levels
against the serotypes 3, 4, 5 and 7 F were below the cut-
off level of at least 0.35 μg/mL and the patient continuedTable 1 Serotype-specific Streptococcus pneumoniae Immunog
unknown hyposplenia suffering from recurrent episodes of in
IPD event, serotype Date Serotype, μg/ml #
1 3 4 5 6B
1st IPD, day 5, 7F 17.08.2008 0.91 0.09 0.20 <0.02 0.58
1st IPD, day 20, 7F 02.09.2008 1.00 0.09 0.23 <0.02 0.59
2nd IPD, day 16, 17F 29.07.2012 2.81 0.38 0.49 0.94 2.54
PCV13 immunization 13.09.2012 ** ** ** ** **
Post-immunization* 30.10.2012 5.62 0.57 0.21 0.41 6.02
3rd IPD, day 3, 17F 06.01.2013 3.23 0.20 0.12 0.18 2.00
#, Blood samples were analyzed for antigen-specific IgG-titers against 14 different p
liquid array modified from Pickering et al. [Pickering JW, Hill HR. Measurement of antib
liquid arrays. Methods Mol Biol. 2012;808:361–75]. The type-specific protective IgG-tite
suggest that titers above 0.35 μg/ml provide protection against invasive pneumo
listed in μg/ml based on the 89SF international standard, except 12 F and 17 F, which
not available.
*Average of two measurements on the same sample.
**, Serotypes covered by the PCV13 vaccine.
n/a, not available.to have apparently not protective levels of antibodies
against serotype 7 F despite the current infection. The
cut-off level of 0.35 μg/mL is recommended by a WHO
Working Group as applicable for assessing the efficacy of
pneumococcal conjugate vaccines and is widely consid-
ered to provide a protective effect against IPD [8]. How-
ever, it should be noted that this recommendation relates
to measurement of antibody-levels after vaccination with
the conjugate vaccines and is based on trials that analyses
protective levels in infants after vaccination [8].
Second episode of IPD
In 2012, the patient was admitted with fever, neck stiff-
ness, confusion, septic shock, DIC and peripheral tissue is-
chemia. Lumbar puncture revealed cerebrospinal fluid
(CSF) with 287 · 106/L leukocytes of which 189 · 106/L
were neutrophils. Cultures of CSF and blood were positive
for S. pneumoniae and later serotyping showed type 17 F.
On admission, blood laboratory analyses showed: leuco-
cyte count 43 · 109/L, platelet count 35 · 109/L, hemoglobin
6.4 mmol/L, C-reactive protein 300 mg/L, creatinine
245 μmol/L, alanine aminotransferase 730 U/L, lactate de-
hydrogenase 2980 U/L, D-dimer 138 mg/L, PP 0.2, INR
2.4, antithrombin 0.42 kIU/l, and fibrinogen 3.1 μmol/L.
Initial empirical treatment for bacterial meningitis was
intravenous ceftriaxone, ampicillin and dexamethasone.
On day 2, the S. pneumoniae strain was found to be fully
sensitive to penicillin, and treatment was changed to high-
dose penicillin G. Infusion of epoprostenol was adminis-
tered due to severe peripheral ischemia. Measurement of
plasma immunoglobulin revealed low IgM at 0.17 g/L, but
normal IgG and IgA, and the patient was treated with
single intravenous infusions of immunoglobulin (IVIG) at
day 3 to day 5. The cochlear implant was suspected to be
the infectious focus, but CT scan of the head withlobulin G titres (IgG) in an adult with previously
vasive pneumococcal disease (IPD)
7F 9V 12F MFI 14 17F MFI 18C 19A 19F 23F
0.13 0.47 239.5 2.97 281,3 1.06 0.67 0.85 1.72
0.17 0.50 250.3 2.73 295.5 0.86 0.77 1.55 1.75
1.23 3.07 387.8 3.49 367.5 2.58 3.14 3.97 5.35
** ** ** ** ** ** **
0.42 5.02 n/a 33.24 n/a 12.32 1.99 2.67 2.48
0.18 2.05 174.5 15.52 198.5 3.84 0.82 0.97 1.31
neumococcal serotypes measured by a Luminex xMAP microsphere-based
odies to pneumococcal polysaccharides with luminex xMAP microsphere-based
rs are unknown. Levels beneath 0.35 μg/ml are marked with bold as studies
coccal disease after vaccination with a conjugated vaccine. IgG-titers are
are listed in mean fluorescence intensity (MFI) because a reference material were
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thoracic and trans-esophageal echocardiography revealed
no signs of endocarditis or cardiovascular abnormalities
and the chest X-ray showed no infiltrates. An ultrasound
investigation of the abdomen was performed, during
which no spleen could be detected, and a subsequent
CT scan of the abdomen and thorax with intravenous
contrast revealed a small irregularly defined and par-
tially calcified mass measuring 3.8 × 2.1 cm interpreted
as a small spleen (Figure 1A). No enlarged lymph nodes
were detected and all other organs were unremarkable.
A Technetium-99 m (99mTc) labelled heat-denatured
red blood cell scintigraphy showed a small rudimentary
spleen (2 cm) at the same location as with the CT scan
(Figure 1B,C), and a blood smear revealed Howell-Jolly bod-
ies (HJB), indicating an impaired function of the spleen
(Figure 1D). No genetic defects were found by analysis of
chromosomes and comparative genomic hybridization array.
The patient recovered to normal consciousness within
day 1 and was discharged on day 16 after two weeks of
treatment with high-dose penicillin G. Persistent mild
cognitive impairment was the only apparent sequelae.
On discharge, ‘stand-by’ antibiotics (amoxicillin/clavu-
lanic acid) for use in case of fever were provided.A
C
Figure 1 CT scan (A), spleen scintigraphy (B, C) and peripheral blood sm
with Streptococcus pneumoniae. A: CT scan showing horizontal section of a
the arrow. B: Scintigraphy after injection of Technetium-99 m (99mTc) labeled,
to the rudimentary spleen seen with the CT scan. C: Tc99m labeled, denatured
the uptake corresponding to the rudimentary spleen seen with the CT scan. D
point at red blood cells with Howell-Jolly bodies (HJB).IgG-antibody-levels against the 14 pneumococcal sero-
types were examined 16 days after admission (Table 1),
and the results suggested protective titers against all 14 se-
rotypes, however, probably influenced by the recent im-
munoglobulin infusion. The patient was vaccinated with
the 13-valent pneumococcal conjugate vaccine (PCV13,
Prevenar 13®, Pfizer) and with the Haemophilus influen-
zae type b (ACT-HIB®, Sanofi Pasteur MSD) vaccine
two months after debut. IgG antibody-levels were eval-
uated one and a half month after vaccination, showing
decreasing average antibody levels from 5.48 μg/mL to
4.42 μg/mL although levels beneath 0.35 μg/mL were
only found against serotype 4 (Table 1).
The patient has three children, at that time aged 2 (M),
4 (F) and 7 (F) years. All three children were healthy with
no obvious signs of immunodeficiency. The children were
examined with abdominal ultrasound in order to detect a
possible hereditary asplenia or hyposplenia. The abdom-
inal ultrasound was normal, except from the finding of a
slightly small spleen in the 4-year old daughter that as
1-year old was hospitalized with pneumococcal meningitis
(serotype 7 F). The children were not evaluated for
Howell-Jolly bodies. All children had normal immuno-
globulin levels including IgG-subtypes and normalB
D
ear (D) of a woman with recurrent episodes of invasive infections
normal liver, while a very small rudimentary spleen is located at the tip of
denatured red blood cells (RBC). The arrow shows uptake corresponding
RBC scintigraphy with different coronal sections of the abdomen showing
: Peripheral blood smear stained with a standard H&E staining. Arrows
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H. influenzae type b. All the children were vaccinated
with the PCV13 vaccine.
Third episode of IPD
The patient was admitted with a third episode of IPD five
and a half month after the second episode. The patient
took stand-by antibiotics prior to admission, but due to
vomiting probably without effect. The symptoms started
less than 24 hours before admission on which the patient
presented with septic shock but without signs of meningi-
tis or neurological dysfunction. Lumbar puncture was per-
formed and CSF contained 12 · 106/L leukocytes of which
2 · 106/L were neutrophils. Again, S. pneumoniae was cul-
tured in blood, but also detected in CSF using PCR with
specific primers for S. pneumoniae. Typing showed infec-
tion with serotype 17 F. The S. pneumoniae strain was
fully sensitive to penicillin, and accordingly the patient
was treated with high-dose penicillin G for two weeks.
The patient rapidly recovered without new sequelae.
Detailed reassessment of the immune function was per-
formed one month after recovery. A mild lymphocyto-
sis with increased concentrations of B cells, increased
concentrations of CD8 T cells , normal fractions of T, B
and NK cells, normal expression of CD45RA/CD45RO
among T cells, but a reduced level of IgM positive mem-
ory B cells and reduced levels of IgM in blood was found.
The proliferative response of CD4 T-cells to stimulation
with CD3/CD28/CD2 or pokeweed mitogen was within
the normal range. In serum day 3 after admission IgG-
pneumococcal-antibody-levels against the 14 serotypes
were measured. It applied to all subtypes that antibody-
levels declined since the post-immunization measure-
ment or regarding 17 F and 12 F since measurements
from the first two episodes of IPD. However, only
antibody-levels against 3, 4, 5 and 7 F were below the cut-
off level of 0.35 μg/mL. Information from the patient’s
history organized as a timeline is summarized in Figure 2.
Conclusions
The patient presented above had no history suggesting
immunodeficiency until the first episode of IPD. However,
when interviewed after the second episode of IPD, she
recalled having had pneumonia about once a year from
about the age of 18 treated by her general practitioner.
Additional information and verification of infectious
episodes could not be obtained. A predisposing med-
ical disease associated to hyposplenia was not suspected
or found. Examination of splenic dysfunction is rarely per-
formed routinely in first-time meningitis unless there is a
specific suspicion. Spleen dysfunction was not suspected
in this patient although the immunological investigation
demonstrated a low level of IgM-positive CD27 memory
B cells, which could represent a sign of spleen dysfunction.Establishing the diagnosis of functional hyposplenia is based
on the spleen filtering function of radiolabelled isotopes or
by detection of morphological erythrocyte abnormalities.
Erythrocyte scintigraphy is currently the best approach
for evaluating functional hyposplenism [9], although
usually not available as a routine investigation. Examin-
ation of peripheral blood for numbers of pitted erythro-
cytes (erythrocytes with characteristic membrane pits)
has proven to be a sensitive method, which accurately cor-
relates with spleen volume, and is therefore used as gold
standard for spleen function in many studies [10]. How-
ever, the method is not widely used, and requires specific
equipment. A more commonly used method is observa-
tion of erythrocytes with nuclear remnants named
Howell-Jolly bodies (HJB) on blood smears. Detection of
HJB is a useful method of screening for asplenia, although
the specificity and sensitivity has been disputed, especially
regarding cases with mild hyposplenia [11–13]. Flowcyto-
metric quantification of HJB is also a useful method [14].
Reduction of spleen size using ultrasound or computed
tomography can be used to detect hyposplenia, but it is
unclear whether non-functional imaging reveals useful
information about risk for severe infections or spleen
function [15].
The patient was vaccinated with the PPV23 vaccine after
the first episode of IPD. However, the antibody response
was never evaluated. After the second episode of IPD, the
antibody response against PPV23 was measured using a
calculated geometrical mean of 12 representative capsule-
types (1, 3, 4, 5, 6B, 7 F, 9 V, 14, 18C, 19A, 19 F), and
interpreted as sufficient. It should be noted that the pa-
tient during the second episode of IPD received treatment
with immunoglobulin and evaluation of protective anti-
bodies did perhaps not reflect the vaccination response,
but rather protection by specific immunoglobulin’s admin-
istered during hospitalization. Eight weeks after the sec-
ond episode of IPD, the patient received a dose of PCV13.
Antibody titers against the 12 representative capsule-types
were evaluated and found to be above the cut-off indicat-
ing protection. As suggested by guidelines, the vaccination
was not followed by PPV23, as the patient received the
first dose of PPV23 four years earlier.
Guidelines by the Advisory Committee on Immunization
Practices (ACIP) recommend prophylactic vaccination
against S. pneumoniae, H. influenzae type b and N. menin-
gitis in patients with spleen dysfunction [12]. Vaccination
at the first opportunity is recommended, and should be
followed by re-immunizations every 5 years [7]. The ACIP
guidelines ) has recently been changed for adults > 19 years
old with immune-compromising conditions due to increas-
ing evidence of immunological hypo-responsiveness induced
by prior vaccination with PPV23 and reduced effectiveness
of PPV23 [16,17]. A primary combined schedule of PCV13




















Daughter (10 mts) IPD
Type 7F




Meningitis, shock, DIC 
14 days with high-dose penicillin G 
Bilateral cochlearim plants 
Discharged
Amputation of four toes
Normal investigation of immune  
function but low levels of IgM
Memory B-cells in blood
Second and third IPD episode 
Meningitis, shock, DIC 
Infusion of IVIG
14 days with high-dose penicillin G 
Normal CT scan
UL abdomen revealed hyposplenia 
Discharged
CT abdomen and red blood cell 
scintigraphy confirmed
hyposplenia
Howell-Jolly bodies in blood smear
Admitted with 3rd IPD
14 days with high-dose penicillin G 
Investigation of immune function
revealed IgM levels and low levels
of IgM memory B-cells in blood 
Figure 2 Timeline of IPD episodes and clinical events.
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9 N, 9 V, 10A, 11A,12 F, 14, 15B, 17 F, 18C, 19 F, 19A, 20,
22 F, 23 F, and 33 F) eight weeks later, and an additional
PPV23 five years later is now recommended [18]. If at least
one dose of PPV23 has been administered previously, a dose
of PCV13 is recommended one year after the last PPV23Table 2 Recommended immunizations against invasive pneu
conjugate vaccine (PCV13) and the 23-valent pneumococcal po
with functional or anatomic asplenia [17]
Vaccination status PCV13 PPV23
Pneumococcal
vaccine-naïve




1 dose of PCV13≥ 1 year after last PPV23 Revaccinatio
and≥ 5 yeadose. For those who require additional doses of PPV23, the
first such dose should be given no sooner than 8 weeks after
PCV13 and at least 5 years after the most recent dose of
PPV23 (Table 2) [18]. The combined use of the heptavalent
conjugate vaccine (PCV7, serotypes 4, 6B, 9 V, 14, 18C, 19 F,
and 23 F) followed by the PPV23 vaccine has provenmococcal disease using the 13-valent pneumococcal
lysaccharide vaccine (PPV23) for adults aged ≥19 years
Antibody measurement
V23≥ 8 weeks after PCV13 Prior to revaccination with PPV23
n with PPV23≥ 5 years after last PPV23
n with PPV23≥ 8 weeks after PCV13
rs after last PPV23
Prior to revaccination with PPV23
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ledge the clinical efficacy of PCV13 and PPV23 in combin-
ation has not yet been evaluated in hyposplenic patients.
The presented case emphasizes that even after vaccin-
ation and when serotype-specific IgG responses seems to
be protective, hyposplenic patients can be vulnerable to
IPD. Currently, measurement of IgG-pneumococcal anti-
bodies does not seem very useful for determining the de-
gree of protection against IPD in hyposplenic patients, and
no studies have established the necessary protective levels.
Moreover, decreased quality of the antibodies and ineffi-
cient cellular immune responses could probably have a
greater impact on the risk of IPD than the actual amount
of antibody in this patient group. Measurement of
specific memory B cells and functional antibodies (op-
sonophagocytic activity, OPA) could further elucidate a
possible hypo-responsiveness, but these studies are not
available in our laboratory, nor are commonly used
methods for assessing vaccination response in most
clinical settings.
In this case the patient received a dose of PPV23 at
the first episode of IPD. Thus, the possibility of
PPV23-induced immunological hypo-responsiveness
upon re-vaccination has to be considered. A recent
study demonstrated impaired antigen-specific B-cell re-
sponses in asplenic patients with β-Thalassemia previously
vaccinated with PPV23. Antigen-specific memory B-cells
and IgG-pneumococcal antibodies were measured, and a
time- and dose-dependent negative effect of previous
PPV23 vaccination was detected [21].
Yearly administration of influenza vaccination is rec-
ommended, because it reduces the risk of secondary
pneumococcal and H. influenzae infection [7]. A recent
study showed a 53% reduced risk of death in asplenic
persons who received influenza immunization compared
to those who had no influenza immunization. Interest-
ingly, no influence on death was seen for pneumococcal
immunization [22].
In patients who fail to have an adequate response to
pneumococcal vaccine it has been proposed that lifelong
antibiotic prophylaxis could be considered [23]. The use
of antibiotics for the prevention of IPD is not evidence
based, and differs between guidelines. Many guidelines
recommend prophylaxis with 250–500 mg per day of
amoxicillin or 500 mg per day of phenoxymethylpenicillin
[7,12,24,25]. No consensus regarding duration of prophy-
laxis exists. British guidelines propose lifelong treatment.
Another approach is access to ‘stand-by’ antibiotics.
‘Stand-by’ antibiotics should be taken at the first sign of
infection if the patient is unable to obtain prompt medical
attention. A strategy with 2 years of prophylactic antibi-
otics followed by the use of emergency or standby antibi-
otics and early presentation to medical care has been
proposed [26]. In the present case the patient receivedstand-by antibiotics after the second episode of IPD and
had a good knowledge of the risk of severe infections, but
nevertheless suffered from another episode of IPD. How-
ever, the third episode was less severe than the first and
second episode, and the patient recovered quickly. This
could probably be explained by earlier initiation of treat-
ment with intravenous antibiotics.
Individuals with predisposing medical conditions and a
history of invasive infections with encapsulated bacteria’s or
recurrent episodes of invasive infections should be referred
to a specialist unit with expert knowledge in infectious dis-
eases and with the ability to perform screening for spleen
dysfunction assessed by erythrocyte scintigraphy, pitted
erythrocyte counting, or Howell-Jolly body detection. If
splenic function is reduced, prevention against infection is
a major priority. Prophylactic initiatives should include
immunization strategies in accordance with current guide-
lines supplemented by stand-by antibiotics and education
of patients and professionals. Sufficient levels of serotype-
specific IgG antibodies do not exclude the possibility of
new episodes of IPD.
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Written informed consent was obtained from the patient
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